

**SUMMARY:** This order extends the withdrawal created by Public Land Order No. 6776 for an additional 20-year period. This extension is necessary to continue protection of the North Cascades Scenic Highway Zone in Chelan, Okanogan, Skagit, and Whatcom Counties, Washington which would otherwise expire on April 17, 2010.

**DATES:** *Effective Date:* April 18, 2010.

**FOR FURTHER INFORMATION CONTACT:** Gregory B. Graham, U.S. Forest Service Okanogan-Wenatchee National Forest, 215 Melody Lane, Wenatchee, Washington 98801, (509) 664-9262, or Charles R. Roy, Bureau of Land Management Oregon/Washington State Office, P.O. Box 2965, Portland, Oregon 97208, (503) 808-6189.

**SUPPLEMENTARY INFORMATION:** The purpose for which the withdrawal was first made requires this extension to continue protection of the unique natural, scenic, and recreational values and the investment of Federal funds along the North Cascades Scenic Highway Zone within the Mt. Baker, Okanogan, and Wenatchee National Forest. The United States Forest Service will continue to manage the lands to protect these values.

**Order**

By virtue of the authority vested in the Secretary of the Interior by Section 204 of the Federal Land Policy and Management Act of 1976, 43 U.S.C. 1714, it is ordered as follows:

1. Public Land Order No. 6776 (55 FR 14422, (1990)) that withdrew 8,950 acres of National Forest System lands from location or entry under the United

States mining laws (30 U.S.C. ch. 2) on behalf of the Forest Service to protect the North Cascades Scenic Highway Zone, is hereby extended for an additional 20-year period.

2. Public Land Order No. 6776 will expire on April 17, 2030, unless, as a result of a review conducted prior to the expiration date, pursuant to Section 204(f) of the Federal Land Policy Management Act of 1976, 43 U.S.C. 1714(f), the Secretary of the Interior determines that the withdrawal shall be extended.

Dated: April 9, 2010.  
**Wilma A. Lewis,**  
*Assistant Secretary—Land and Minerals Management.*  
[FR Doc. 2010-8778 Filed 4-15-10; 8:45 am]  
**BILLING CODE 3410-11-P**

**INTERNATIONAL TRADE COMMISSION**

[USITC SE-10-011]

**Government in the Sunshine Act Meeting Notice; Change of Time of Commission Meeting**

**AGENCY HOLDING THE MEETING:** United States International Trade Commission.  
**ORIGINAL DATE AND TIME:** April 15, 2010 at 11 a.m.  
**NEW DATE AND TIME:** April 15, 2010 at 2:30 p.m.  
**PLACE:** Room 101, 500 E Street SW., Washington, DC 20436, Telephone: (202) 205-2000.  
**STATUS:** Open to the public.  
In accordance with 19 CFR 201.37(a), the Commission has determined to

reschedule the above referenced Commission meeting from 11 a.m. to 2:30 p.m. on April 15, 2010. Earlier announcement of this rescheduling was not possible.

Issued: April 13, 2010.  
By order of the Commission.  
**William R. Bishop,**  
*Hearings and Meetings Coordinator.*  
[FR Doc. 2010-8852 Filed 4-14-10; 11:15 am]  
**BILLING CODE 7020-02-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Importer of Controlled Substances; Notice of Application**

Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in schedule I or II, and prior to issuing a regulation under 21 U.S.C. 952(a)(2) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with Title 21 Code of Federal Regulations (CFR), 1301.34(a), this is notice that on February 15, 2010, Lipomed, Inc., One Broadway, Cambridge, Massachusetts 02142, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedules I and II:

Drug	Schedule
Cathinone (1235) .....	I
Methcathinone (1237) .....	I
N-Ethylamphetamine (1475) .....	I
Fenethylamine (1503) .....	I
Methaqualone (2565) .....	I
Gamma Hydroxybutyric Acid (2010) .....	I
Lysergic acid diethylamide (7315) .....	I
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (7348) .....	I
Marihuana (7360) .....	I
Tetrahydrocannabinols (7370) .....	I
Mescaline (7381) .....	I
3,4,5-Trimethoxyamphetamine (7390) .....	I
4-Bromo-2,5-dimethoxyamphetamine (7391) .....	I
4-Bromo-2,5-dimethoxyphenethylamine (7392) .....	I
4-Methyl-2,5-dimethoxyamphetamine (7395) .....	I
2,5-Dimethoxyamphetamine (7396) .....	I
2,5-Dimethoxy-4-ethylamphetamine (7399) .....	I
3,4-Methylenedioxyamphetamine (7400) .....	I
3,4-Methylenedioxy-N-ethylamphetamine (7404) .....	I
3,4-Methylenedioxymethamphetamine (7405) .....	I
4-Methoxyamphetamine (7411) .....	I
Dimethyltryptamine (7435) .....	I
Psilocybin (7437) .....	I
Psilocyn (7438) .....	I
N-Benzylpiperazine (7493) .....	I

Drug	Schedule
Acetyldihydrocodeine (9051) .....	I
Dihydromorphine (9145) .....	I
Heroin (9200) .....	I
Normorphine (9313) .....	I
Pholcodine (9314) .....	I
Tilidine (9750) .....	I
3-Methylfentanyl (9813) .....	I
Amphetamine (1100) .....	II
Methamphetamine (1105) .....	II
Methylphenidate (1724) .....	II
Amobarbital (2125) .....	II
Pentobarbital (2270) .....	II
Secobarbital (2315) .....	II
Phencyclidine (7471) .....	II
Phenylacetone (8501) .....	II
Cocaine (9041) .....	II
Codeine (9050) .....	II
Dihydrocodeine (9120) .....	II
Oxycodone (9143) .....	II
Hydromorphone (9150) .....	II
Benzoyllecgonine (9180) .....	II
Ethylmorphine (9190) .....	II
Hydrocodone (9193) .....	II
Levorphanol (9220) .....	II
Meperidine (9230) .....	II
Methadone (9250) .....	II
Dextropropoxyphene, bulk (non-dosage forms) (9273) .....	II
Morphine (9300) .....	II
Thebaine (9333) .....	II
Oxymorphone (9652) .....	II
Alfentanil (9737) .....	II
Sufentanil (9740) .....	II
Fentanyl (9801) .....	II

The company plans to import analytical reference standards for distribution to its customers for research and analytical purposes.

Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file comments or objections to the issuance of the proposed registration, and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43, and in such form as prescribed by 21 CFR 1316.47.

Any such comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than May 17, 2010.

This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the **Federal Register** on September 23, 1975, (40 FR 43745-46), all applicants for registration to import a basic class of any controlled substance in schedule I or II are, and will continue to be, required to demonstrate to the Deputy

Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

Dated: March 29, 2010.

**Joseph T. Rannazzisi,**  
*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 2010-8792 Filed 4-15-10; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Application**

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on February 23, 2010, Siemens Healthcare Diagnostics Inc., *Attn:* RA, 100 GBC Drive, Mail Stop 514, Newark, Delaware 19702, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:

Drug	Schedule
Tetrahydrocannabinols (7370) .....	I
Ecgonine (9180) .....	II
Morphine (9300) .....	II

The company utilizes the listed controlled substances in bulk to manufacture in-vitro diagnostic test kits. The company distributes the test kits for sale to its customers. The process used in manufacturing the test kits irreversibly alters the controlled substances involved in such a manner that they are no longer classified as controlled substances as defined under the Controlled Substances Act.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than June 15, 2010.